In late July, the Government Accountability Office released a report on how the lack of effective communications between the Drug Enforcement Agency and both pharmaceutical distributors and chain pharmacy headquarters has impacted legitimate access to pain medicines. "The agency’s report further validates the need for bipartisan, bicameral legislation," according to NACDS.
On Friday, Stichting Preferred Shares Mylan, an independent foundation established in the Netherlands, announced that it would exercise its full call option to purchase 488,388,431 preferred shares in Mylan.
The Food and Drug Administration announced Friday that it approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and cirrhosis.
America’s biopharmaceutical research companies are currently developing 420 medicines for patients suffering from neurological disorders, including epilepsy, Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.